Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trehalose - Seelos Therapeutics

Next Previous
Drug Profile

Trehalose - Seelos Therapeutics

Alternative Names: Cabaletta; SLS-005; Trehalose dihydrate

Latest Information Update: 23 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioblast Pharma
  • Developer Bioblast Pharma; Mashhad University of Medical Sciences; Massachusetts General Hospital; Seelos Therapeutics; Team Sanfilippo Foundation
  • Class Antidementias; Disaccharides; Glucans; Pyrrolidines; Small molecules
  • Mechanism of Action Autophagy stimulants; Protein aggregation inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oculopharyngeal muscular dystrophy; Machado-Joseph Disease; Spinocerebellar ataxias; Amyotrophic lateral sclerosis; Mucopolysaccharidosis III
  • New Molecular Entity No

Highest Development Phases

  • Phase III Oculopharyngeal muscular dystrophy
  • Phase II/III Amyotrophic lateral sclerosis; Spinocerebellar ataxias
  • Phase II Huntington's disease; Machado-Joseph Disease; Mucopolysaccharidosis III
  • Preclinical Alzheimer's disease; Neurodegenerative disorders
  • Discontinued X-linked bulbo-spinal atrophy

Most Recent Events

  • 19 Mar 2024 Seelos Therapeutics plans to request a meeting with US FDA to discuss steps following failure to meet phase II/III HEALEY ALS trial's primary and secondary endpoint
  • 19 Mar 2024 Efficacy data from a phase II/III trial HEALEY ALS trial in Amytrophic lateral scelrosis released by Seelos
  • 27 Oct 2023 Updated pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Seelos Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top